Literature DB >> 29198436

Reprogramming Tumor Blood Vessels for Enhancing Immunotherapy.

Martina Schmittnaegel1, Michele De Palma2.   

Abstract

Angiogenic blood vessels contribute to generating an immunosuppressive tumor microenvironment, in part by limiting the extravasation of T cells. Functional reprogramming of angiogenic blood vessels, for example through angiopoietin-2 blockade, may improve T cell trafficking in tumors and the efficacy of immune checkpoint blockade (ICB) and other cancer immunotherapies.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29198436     DOI： 10.1016/j.trecan.2017.10.002

Source DB:  PubMed          Journal:  Trends Cancer        ISSN： 2405-8025


  17 in total

Review 1.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.

Authors:  Kabir A Khan; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2018-02-13       Impact factor: 66.675

Review 2.  Consensus guidelines for the use and interpretation of angiogenesis assays.

Authors:  Patrycja Nowak-Sliwinska; Kari Alitalo; Elizabeth Allen; Andrey Anisimov; Alfred C Aplin; Robert Auerbach; Hellmut G Augustin; David O Bates; Judy R van Beijnum; R Hugh F Bender; Gabriele Bergers; Andreas Bikfalvi; Joyce Bischoff; Barbara C Böck; Peter C Brooks; Federico Bussolino; Bertan Cakir; Peter Carmeliet; Daniel Castranova; Anca M Cimpean; Ondine Cleaver; George Coukos; George E Davis; Michele De Palma; Anna Dimberg; Ruud P M Dings; Valentin Djonov; Andrew C Dudley; Neil P Dufton; Sarah-Maria Fendt; Napoleone Ferrara; Marcus Fruttiger; Dai Fukumura; Bart Ghesquière; Yan Gong; Robert J Griffin; Adrian L Harris; Christopher C W Hughes; Nan W Hultgren; M Luisa Iruela-Arispe; Melita Irving; Rakesh K Jain; Raghu Kalluri; Joanna Kalucka; Robert S Kerbel; Jan Kitajewski; Ingeborg Klaassen; Hynda K Kleinmann; Pieter Koolwijk; Elisabeth Kuczynski; Brenda R Kwak; Koen Marien; Juan M Melero-Martin; Lance L Munn; Roberto F Nicosia; Agnes Noel; Jussi Nurro; Anna-Karin Olsson; Tatiana V Petrova; Kristian Pietras; Roberto Pili; Jeffrey W Pollard; Mark J Post; Paul H A Quax; Gabriel A Rabinovich; Marius Raica; Anna M Randi; Domenico Ribatti; Curzio Ruegg; Reinier O Schlingemann; Stefan Schulte-Merker; Lois E H Smith; Jonathan W Song; Steven A Stacker; Jimmy Stalin; Amber N Stratman; Maureen Van de Velde; Victor W M van Hinsbergh; Peter B Vermeulen; Johannes Waltenberger; Brant M Weinstein; Hong Xin; Bahar Yetkin-Arik; Seppo Yla-Herttuala; Mervin C Yoder; Arjan W Griffioen
Journal:  Angiogenesis       Date:  2018-08       Impact factor: 9.596

3.  STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.

Authors:  Hannah Yang; Won Suk Lee; So Jung Kong; Chang Gon Kim; Joo Hoon Kim; Sei Kyung Chang; Sewha Kim; Gwangil Kim; Hong Jae Chon; Chan Kim
Journal:  J Clin Invest       Date:  2019-07-25       Impact factor: 14.808

Review 4.  Physiological Perspective on Therapies of Lymphatic Vessels.

Authors:  Witold W Kilarski
Journal:  Adv Wound Care (New Rochelle)       Date:  2018-07-01       Impact factor: 4.730

5.  Immunoactivating the tumor microenvironment enhances immunotherapy as predicted by integrative computational model.

Authors:  Aleksander S Popel
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-26       Impact factor: 11.205

Review 6.  Recent Developments of Systemic Chemotherapy for Gastric Cancer.

Authors:  Hiroyuki Arai; Takako Eguchi Nakajima
Journal:  Cancers (Basel)       Date:  2020-04-28       Impact factor: 6.639

7.  Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance.

Authors:  Dhanya K Nambiar; Todd Aguilera; Hongbin Cao; Shirley Kwok; Christina Kong; Joshua Bloomstein; Zemin Wang; Vangipuram S Rangan; Dadi Jiang; Rie von Eyben; Rachel Liang; Sonya Agarwal; A Dimitrios Colevas; Alan Korman; Clint T Allen; Ravindra Uppaluri; Albert C Koong; Amato Giaccia; Quynh Thu Le
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

Review 8.  Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.

Authors:  Kabir A Khan; Florence Th Wu; William Cruz-Munoz; Robert S Kerbel
Journal:  EMBO Mol Med       Date:  2021-06-14       Impact factor: 12.137

Review 9.  The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy.

Authors:  Diana Klein
Journal:  Front Oncol       Date:  2018-09-10       Impact factor: 6.244

10.  Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.

Authors:  Abhishek S Kashyap; Martina Schmittnaegel; Nicolò Rigamonti; Daniela Pais-Ferreira; Philipp Mueller; Melanie Buchi; Chia-Huey Ooi; Matthias Kreuzaler; Petra Hirschmann; Alan Guichard; Natascha Rieder; Ruben Bill; Frank Herting; Yvonne Kienast; Stefan Dirnhofer; Christian Klein; Sabine Hoves; Carola H Ries; Emily Corse; Michele De Palma; Alfred Zippelius
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-30       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.